The researchers found that two of the patients who received the treatment had significantly reduced their liver tumors
A US study showed that Regorafenib significantly improves the survival of patients with advanced liver cancer.
The study was conducted by researchers at the Tisch Cancer Institute of the Mount Sinai Hospital in the United States and was published Wednesday in the Lancet medical journal.
The results showed that the drug helped improve patient survival for an average of 10.6 months, compared with 7.8 months for patients who took placebo.
The researchers also found that two of the patients who received treatment had significantly reduced their malignant tumors.